BACKGROUND: Nonsurgical modalities are sometimes advocated as the standard of care for advanced oropharyngeal tumors. Oncologic and functional results have been modest. The aim of our study was to evaluate outcomes of a minimally invasive approach, using transoral laser microsurgery (TLM) as the primary treatment for advanced oropharyngeal carcinoma. METHODS: A prospectively assembled database of 204 patients with American Joint Committee on Cancer (AJCC) stages III and IV tonsil or tongue base cancer, treated primarily with TLM during 1996-2006 at 3 centers with minimum 2-year follow-up was analyzed. Survival, locoregional control, and swallowing status were recorded. RESULTS: Mean follow-up was 49 months and 79.4% of patients were alive. Three-year overall survival, disease-specific survival, and disease-free survival were 86%, 88%, and 82%, respectively. Local control was 97%, and 87% of patients had normal swallowing or episodic dysphagia. CONCLUSIONS: TLM as a primary treatment for advanced oropharyngeal malignancy confers excellent survival and swallowing proficiency.
BACKGROUND: Nonsurgical modalities are sometimes advocated as the standard of care for advanced oropharyngeal tumors. Oncologic and functional results have been modest. The aim of our study was to evaluate outcomes of a minimally invasive approach, using transoral laser microsurgery (TLM) as the primary treatment for advanced oropharyngeal carcinoma. METHODS: A prospectively assembled database of 204 patients with American Joint Committee on Cancer (AJCC) stages III and IV tonsil or tongue base cancer, treated primarily with TLM during 1996-2006 at 3 centers with minimum 2-year follow-up was analyzed. Survival, locoregional control, and swallowing status were recorded. RESULTS: Mean follow-up was 49 months and 79.4% of patients were alive. Three-year overall survival, disease-specific survival, and disease-free survival were 86%, 88%, and 82%, respectively. Local control was 97%, and 87% of patients had normal swallowing or episodic dysphagia. CONCLUSIONS:TLM as a primary treatment for advanced oropharyngeal malignancy confers excellent survival and swallowing proficiency.
Authors: Martin Canis; Friedrich Ihler; Hendrik A Wolff; Hans Christiansen; Christoph Matthias; Wolfgang Steiner Journal: Eur Arch Otorhinolaryngol Date: 2012-07-05 Impact factor: 2.503
Authors: Alpen B Patel; Michael L Hinni; Taylor R Pollei; Richard E Hayden; Eric J Moore Journal: Eur Arch Otorhinolaryngol Date: 2015-02-08 Impact factor: 2.503
Authors: William M Mendenhall; Primož Strojan; Carl E Silver; Randall P Owen; Alessandra Rinaldo; Ashok R Shaha; Avraham Eisbruch; Robert P Takes; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2013-10-20 Impact factor: 2.503
Authors: P Sinha; W T Thorstad; B Nussenbaum; B H Haughey; D R Adkins; D Kallogjeri; J S Lewis Journal: Oral Oncol Date: 2013-11-06 Impact factor: 5.337
Authors: Vlad C Sandulache; John Hamblin; Syeling Lai; Todd Pezzi; Heath D Skinner; Numan A Khan; Shayan M Dioun; Christine Hartman; Jennifer Kramer; Elizabeth Chiao; Xiaodong Zhou; Jose P Zevallos Journal: Head Neck Date: 2015-07-04 Impact factor: 3.147
Authors: Shamir P Chandarana; Julia S Lee; Eric J P Chanowski; Assuntina G Sacco; Carol R Bradford; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Avraham Eisbruch; Francis P Worden; Thomas J Giordano; Bhavna Kumar; Katrina G Cordell; Thomas E Carey; Douglas B Chepeha Journal: Head Neck Date: 2012-08-21 Impact factor: 3.147